Cash for quitting: new study tests rewards and meds to help HIV patients stop smoking

NCT ID NCT04490057

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested different ways to help people living with HIV quit smoking. Participants received nicotine replacement therapy (like patches or gum), the medications varenicline or bupropion, and financial rewards for staying smoke-free. The goal was to see if these approaches could reduce the number of cigarettes smoked per day. The study enrolled 323 adults with HIV who smoked at least 5 cigarettes daily.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler, varenicline, bupropion
What this could lead to
If successful, this could point toward effective, personalized ways to help people with HIV quit smoking, reducing their risk of smoking-related diseases.
What could go wrong
This is a completed Phase 4 study, but results may not apply to all smokers with HIV. Self-reported smoking reduction may be less reliable than objective measures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bridgeport Hospital Infectious Disease Clinic

    Bridgeport, Connecticut, 06110, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • SUNY Downstate STAR Clinic

    Brooklyn, New York, 11203, United States

  • Yale University School of Medicine

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.